ABBV · 8-K · 20260706PR000021
Guidance / Outlook
AbbVie Inc. · 2026-07-06 · Importance 62 · Surprise 68 · In source text
AbbVie revised its 2026 adjusted diluted EPS guidance to $13.91–$14.11 from the previously announced $14.08–$14.28 range. The revision reflects $291 million of acquired in-process research and development (IPR&D) and milestones expense incurred in the second quarter of 2026, reducing adjusted diluted EPS guidance by $0.17. Including the second-quarter expense, total acquired IPR&D and milestones expense reflected in full-year guidance is $1.035 billion. The company stated that its 2026 adjusted diluted EPS guidance excludes any additional acquired IPR&D and milestones expense beyond the second quarter because such costs cannot be reliably forecasted.
Key facts
- Guidance including Q2 2026 acquired IPR&D and milestones expense Acquired IPR&D and Milestones Expense for the Full-Year Ended December 31, 2026: $1,035 source
- Previously announced guidance excluding Q2 2026 acquired IPR&D and milestones expense Acquired IPR&D and Milestones Expense for the Full-Year Ended December 31, 2026: $744 source
- Previously announced guidance excluding Q2 2026 acquired IPR&D and milestones expense Adjusted Diluted EPS Range for the Quarter Ended June 30, 2026: $3.74 to $3.78 source
- Previously announced guidance excluding Q2 2026 acquired IPR&D and milestones expense Adjusted Diluted EPS Range for the Full-Year Ended December 31, 2026: $14.08 to $14.28 source
- Guidance including Q2 2026 acquired IPR&D and milestones expense Adjusted Diluted EPS Range for the Quarter Ended June 30, 2026: $3.57 to $3.61 source
- Guidance including Q2 2026 acquired IPR&D and milestones expense Adjusted Diluted EPS Range for the Full-Year Ended December 31, 2026: $13.91 to $14.11 source
- Q2 2026 acquired IPR&D and milestones expense: $291 source
- The Company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2026 source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | committed | -5.2% | Guidance including Q2 2026 acquired IPR&D and milestones expense Acquired IPR&D and Milestones Expense for the Full-Year Ended December… |
| net_income | negative | committed | — | Guidance including Q2 2026 acquired IPR&D and milestones expense Adjusted Diluted EPS Range for the Quarter Ended June 30, 2026: $3.57 to… |
| net_income | negative | committed | — | Guidance including Q2 2026 acquired IPR&D and milestones expense Adjusted Diluted EPS Range for the Full-Year Ended December 31, 2026:… |